drugset / Trial / NCT03804996
Study of TG-1801 in Subjects With B-Cell Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase 1 first in human Study to Assess the Bispecific Antibody TG-1801 in Subjects with B-Cell Lymphoma
Timeline
- Start
- 2019-03-05
- Primary completion
- 2024-02-21
- Completion
- 2024-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ublituximab | Monoclonal antibody | — | Intravenous |
| Subject | ZERIPATAMIG | Monoclonal antibody | — | Intravenous |